For some years now, the application of digital technology in health care has promised to advance patient-focused outcomes to reduce costs across a very fragmented ecosystem. To their credit, life sciences companies have made investments in this area, to some success. But they have yet to move beyond pills and apps at the pilot stage to fully embrace a business model geared to an at-scale state of convergence between health care and digital. Instead, life sciences companies have largely opted to acquire or partner with technology innovators for point solutions.
EY’s 2018 Digital Deal Economy Study surveyed 900 global executives, including more than 70 in life sciences. Its findings portray how digital technology increasingly drives the strategy behind biopharma deal-making...
